Pramipexole Teva: Uses, Dosage & Side Effects
A generic non-ergot dopamine agonist (pramipexole) for Parkinson's disease and moderate to severe restless legs syndrome
Pramipexole Teva is a generic formulation of pramipexole, a selective, non-ergot dopamine agonist with a high affinity for the D3 dopamine receptor subtype. It is licensed for the treatment of the signs and symptoms of idiopathic Parkinson's disease — as monotherapy in early disease or as add-on therapy with levodopa in advanced disease — and for the symptomatic treatment of moderate to severe primary restless legs syndrome (RLS) in adults. The 0.088 mg tablet represents the lowest available strength of pramipexole (base) and is used both for initiation and slow dose titration. The medication is prescription only and requires gradual up-titration as well as carefully supervised tapering on discontinuation.
Quick Facts: Pramipexole Teva
Key Takeaways
- Pramipexole Teva (pramipexole) is a non-ergot dopamine agonist approved for idiopathic Parkinson's disease and moderate to severe primary restless legs syndrome, recommended by international guidelines including the Movement Disorder Society and the American Academy of Sleep Medicine.
- The 0.088 mg strength expresses pramipexole as the base; in some countries the same tablet is labelled as 0.125 mg of the dihydrochloride monohydrate salt — these are identical pharmacologically.
- Dose must be titrated slowly — typically doubled every 5–7 days for Parkinson's disease and every 4–7 days for restless legs syndrome — to minimize nausea, dizziness and orthostatic hypotension.
- Pramipexole can cause sudden onset of sleep without warning and clinically important impulse control disorders including pathological gambling, hypersexuality and compulsive shopping. Patients and carers should be explicitly informed before treatment starts.
- Pramipexole should never be stopped abruptly because of the risk of dopamine agonist withdrawal syndrome (DAWS) and, very rarely, a neuroleptic malignant syndrome-like reaction. Always taper under medical supervision and adjust the dose in renal impairment.
What Is Pramipexole Teva and What Is It Used For?
Pramipexole Teva contains pramipexole dihydrochloride monohydrate, a small molecule that directly activates dopamine receptors in the central nervous system. Unlike levodopa, which must first be converted into dopamine inside the brain, pramipexole binds to post-synaptic D2 and D3 receptors itself and mimics the action of endogenous dopamine. It is classified as a non-ergot dopamine agonist, distinguishing it from older ergoline-derived agents such as bromocriptine, cabergoline and pergolide, which were associated with a risk of cardiac valvulopathy and retroperitoneal fibrosis. The non-ergot agonists — pramipexole, ropinirole and rotigotine — are today the preferred first-line dopamine agonists worldwide.
The medication is licensed for two distinct indications. The first is the symptomatic treatment of idiopathic (primary) Parkinson's disease. In early Parkinson's disease, pramipexole can be used as monotherapy to improve bradykinesia, rigidity and tremor, often deferring the need for levodopa and the long-term motor complications associated with it. In advanced disease, pramipexole is added to levodopa when the latter alone no longer provides smooth motor control, helping to reduce levodopa dose requirements, smoothing out "wearing-off" fluctuations and improving quality of life. Evidence for the efficacy of pramipexole comes from randomized controlled trials such as the CALM-PD study and extensive post-marketing experience over more than two decades.
The second licensed indication is the symptomatic treatment of moderate to severe primary restless legs syndrome (RLS) in adults, at daily doses up to 0.54 mg of pramipexole base. RLS is a sensorimotor disorder characterized by an urge to move the legs, usually accompanied by uncomfortable sensations, which worsens during rest in the evening and night and is temporarily relieved by movement. Dopaminergic pathways are strongly implicated in RLS pathophysiology, and pramipexole reduces both the motor urge and the associated sleep disturbance. Current guidelines (American Academy of Sleep Medicine, European Restless Legs Syndrome Study Group, International Restless Legs Syndrome Study Group) now recommend that alpha-2-delta ligands (gabapentin enacarbil, pregabalin) be considered as first-line for many patients because of the long-term risk of augmentation — a paradoxical worsening of symptoms — with dopamine agonists, but pramipexole remains an important option.
Pramipexole is not a cure and does not modify the underlying progression of Parkinson's disease. Its role is purely symptomatic: to replace or augment the action of dopamine, whose production is progressively lost as dopaminergic neurons of the substantia nigra pars compacta degenerate. The clinical response is typically apparent within days of reaching an effective dose, and benefits persist as long as treatment continues and adherence is maintained. Once an effective dose has been established, pramipexole can be used for many years, although treatment should always be regularly reviewed by a specialist to weigh ongoing benefit against adverse effects such as impulse control disorders, daytime sleepiness or augmentation in RLS.
Pramipexole Teva is a generic product marketed by Teva Pharmaceutical Industries, the world's largest manufacturer of generic medicines. It contains exactly the same active substance, at the same strength, as the originator products Mirapex (United States), Sifrol (Europe) and Mirapexin (Europe), and is bioequivalent to them in regulatory studies submitted to the European Medicines Agency and national authorities. Because it is a generic, it is usually less expensive than the originator brands, yet it is expected to produce the same clinical effect. Patients should nevertheless be aware that switching between brands or generics of pramipexole may occasionally lead to minor changes in tolerability owing to different excipients; any concerns about switching, tablet appearance or unexpected adverse effects should be discussed with the prescribing doctor or pharmacist.
What Should You Know Before Taking Pramipexole Teva?
Contraindications
Pramipexole Teva must not be used when any of the following apply. Understanding these contraindications is essential for safe prescribing and for the prevention of serious adverse events:
- Hypersensitivity: Known allergy or hypersensitivity to pramipexole or to any of the excipients listed in the product's patient information leaflet.
- Severe cardiovascular disease: Pramipexole should be used with great caution, and only after specialist assessment, in patients with severe cardiovascular disease because of the risk of orthostatic hypotension and, very rarely, cardiac failure.
- Severe renal impairment without dose adjustment: Because pramipexole is cleared almost entirely by the kidneys, use without appropriate dose reduction in significant renal impairment is not recommended.
- Pregnancy and breastfeeding: Pramipexole is not recommended in pregnancy unless clearly necessary, and its use is contraindicated during breastfeeding because it may suppress prolactin secretion and interfere with milk production.
Pramipexole can cause abrupt, unpredictable episodes of sleep onset without preceding warning signs of drowsiness. These "sleep attacks" have occurred during normal daily activities, including while driving, and have led to traffic accidents. Do not drive or operate machinery until you know how this medicine affects you. If you experience sudden sleep onset, stop driving and inform your doctor immediately.
Warnings and Precautions
Before starting Pramipexole Teva, inform your doctor if you have, have ever had, or develop any of the following conditions, as additional monitoring, dose reductions or alternative therapy may be required:
- Kidney disease: Renal impairment significantly reduces the clearance of pramipexole. Your doctor will measure creatinine or estimate glomerular filtration rate (eGFR) before starting and periodically during treatment. Dose and dosing frequency must be reduced if kidney function is impaired.
- History of psychosis, hallucinations or confusion: Dopamine agonists can precipitate or worsen psychotic symptoms, particularly visual hallucinations. They are generally avoided in patients with a history of non-drug-induced psychotic illness.
- History of impulse control disorders: A personal or family history of pathological gambling, binge eating, compulsive shopping, hypersexuality or substance use disorders may increase the risk of developing impulse control disorders on pramipexole. These risks should be discussed in advance with the patient and the family.
- Cardiovascular disease: Orthostatic hypotension (a fall in blood pressure on standing) can occur, particularly during dose titration. Blood pressure should be monitored in patients with heart disease or those taking antihypertensive medication.
- Ophthalmological changes: Pramipexole has been associated with a small risk of visual disturbances, including blurred vision. Regular eye examinations are recommended if visual symptoms develop.
- Severe mental illness: Depression, suicidal ideation and anxiety can occur or worsen with dopamine agonist therapy. Any new or worsening mood symptoms should be reported promptly.
- Augmentation (RLS only): In restless legs syndrome, long-term use of dopamine agonists can lead to augmentation, in which symptoms become more severe, start earlier in the day and spread to other body parts. If this occurs, the dose may need to be reduced or pramipexole replaced by an alternative agent such as gabapentin enacarbil or pregabalin.
Pramipexole, like other dopamine agonists, can trigger impulse control disorders including pathological gambling, compulsive shopping or spending, binge eating, hypersexuality (markedly increased sexual drive or thoughts) and punding (stereotyped, repetitive purposeless activities). These behaviours can cause serious personal and financial harm. Inform your doctor and your family about the risk before treatment starts, and tell your doctor at once if any such behaviour develops or changes. Dose reduction or discontinuation usually resolves the problem.
Patients should be informed that sleep attacks, orthostatic hypotension and hallucinations can occur and can be dose-related. They should also be warned about fluid retention and peripheral oedema, which can develop insidiously. Sudden, unexplained weight gain, swelling of the ankles or shortness of breath should prompt medical review. If any of these occur, do not stop pramipexole abruptly; contact your prescriber for advice on dose adjustment or tapering.
Pramipexole's effect on blood pressure should be taken seriously in older adults, who are more susceptible to falls. Changing position slowly, ensuring adequate hydration and reviewing concurrent antihypertensive medication can all help reduce the risk of falls. In patients with Parkinson's disease, a combined assessment of motor symptoms, cognition, mood and autonomic function is recommended before and during treatment.
Pregnancy and Breastfeeding
The safety of pramipexole in human pregnancy has not been established. Animal studies have shown reproductive toxicity at high doses. Pramipexole Teva should therefore only be used during pregnancy if the expected benefit to the mother outweighs the potential risk to the fetus. Women of childbearing potential should discuss contraception with their doctor before starting treatment. If pregnancy occurs during treatment, the prescriber should be contacted immediately to review options, because abrupt withdrawal of the medication also carries risks.
Pramipexole inhibits secretion of prolactin and can suppress lactation. It may also pass into breast milk. For these reasons, pramipexole should not be used by women who are breastfeeding. If pramipexole treatment is clinically necessary in a breastfeeding mother, breastfeeding should be stopped.
Driving and Operating Machinery
Pramipexole has a moderate to major influence on the ability to drive and use machines. It can cause drowsiness and, more importantly, sudden episodes of sleep onset without the usual warning signs. Patients who experience daytime sleepiness or sleep attacks, or who start new central nervous system depressant medication, should not drive or undertake activities where impaired alertness could put themselves or others at risk. They should refrain from driving and operating machinery until these episodes have been resolved, following medical advice.
Other Practical Precautions
Tell any doctor, dentist or pharmacist treating you that you are taking pramipexole. This is particularly important before any planned surgery, as the medication will usually need to be continued where possible to avoid withdrawal symptoms and worsening of Parkinson's symptoms. If an operation requires fasting, a tailored plan for dosing around the procedure should be agreed with the neurologist. Patients travelling across time zones should plan dosing times in advance to avoid missing doses.
How Does Pramipexole Teva Interact with Other Drugs?
Pramipexole is not metabolized by cytochrome P450 enzymes and is eliminated almost entirely unchanged by active tubular secretion in the kidneys. This unusual pharmacokinetic profile means that most classical CYP-mediated drug interactions do not apply, but interactions involving renal transporters (especially the organic cation transporter OCT2) and interactions based on overlapping pharmacology are important. Always inform your doctor and pharmacist about every medicine you take, including over-the-counter drugs, herbal products and supplements.
Major Interactions
| Interacting Drug or Class | Effect | Clinical Significance |
|---|---|---|
| Antipsychotics (haloperidol, risperidone, olanzapine, chlorpromazine, fluphenazine) | Dopamine receptor blockade opposes pramipexole's action; can worsen Parkinson's disease and precipitate motor deterioration | Avoid where possible. If antipsychotic cover is essential, specialists prefer clozapine or quetiapine, which have much weaker D2 blockade |
| Metoclopramide | Central dopamine antagonism; reduces pramipexole efficacy and can cause drug-induced parkinsonism | Avoid. Domperidone is a preferred antiemetic for patients on dopamine agonists (does not readily cross the blood-brain barrier) |
| Cimetidine | Inhibits renal tubular secretion of pramipexole via OCT2; increases plasma concentration by approximately 50% | Monitor for increased side effects. An alternative H2 blocker or proton-pump inhibitor is usually preferred |
| Amantadine | Additive dopaminergic effect; competes for renal tubular secretion; may increase pramipexole exposure | Can be used together in Parkinson's disease but monitor for increased side effects including hallucinations |
| Sedatives, hypnotics, alcohol and opioids | Additive central nervous system depression; increased sedation, dizziness and risk of sleep attacks | Minimize concurrent use. Avoid alcohol, especially during dose titration |
Moderate Interactions and Common Co-prescriptions
| Interacting Drug or Class | Effect | Clinical Guidance |
|---|---|---|
| Levodopa | Additive dopaminergic effect; may increase dyskinesias and hallucinations | Intentional combination in advanced Parkinson's. Consider reducing levodopa dose by 10–30% when pramipexole is added or increased |
| Antihypertensives (ACE inhibitors, diuretics, beta blockers) | Additive hypotensive effect; increased orthostatic hypotension and risk of falls | Monitor blood pressure, especially during dose titration. Review antihypertensive dose if symptomatic orthostatism occurs |
| Selective MAO-B inhibitors (rasagiline, selegiline, safinamide) | Additive dopaminergic effect; generally safe at licensed doses | Commonly co-prescribed. Monitor for nausea, hallucinations and dyskinesias |
| COMT inhibitors (entacapone, opicapone, tolcapone) | Prolongs levodopa effect when used in triple therapy; no direct pramipexole interaction | Safe combination. Watch for additive dyskinesias and diarrhoea (entacapone, tolcapone) |
| Other cationic drugs secreted by OCT2 (ranitidine, trimethoprim, quinidine, procainamide) | Competition for renal tubular secretion; may modestly increase pramipexole levels | Monitor for increased side effects; no routine dose change required |
| Anticholinergics (trihexyphenidyl, biperiden) | Additive antiparkinsonian effect; increased risk of confusion and hallucinations, especially in elderly | Use with caution. Anticholinergics are generally avoided in patients >65 years |
Pramipexole can be taken with or without food. Taking it with food does not affect total absorption but may reduce nausea during the first weeks of treatment. Unlike levodopa, pramipexole is not clinically affected by dietary protein. Alcohol should be avoided or strictly limited, especially during dose titration and whenever sleep attacks are a concern, because both substances independently increase drowsiness.
What Is the Correct Dosage of Pramipexole Teva?
Pramipexole Teva is dosed according to pramipexole base in most European and international product information. Because the 0.088 mg tablet contains 0.125 mg of pramipexole dihydrochloride monohydrate (salt), some older labelling and parts of the North American market use the salt-based nomenclature. The two conventions describe the same tablet; this article uses the base convention throughout unless stated otherwise. Treatment should always be initiated and titrated by a physician familiar with the use of dopamine agonists.
Adults — Parkinson's Disease
Starting Dose
Week 1: take one 0.088 mg tablet three times a day (total 0.264 mg/day). Doses should be spread evenly throughout the day, approximately every 8 hours. Taking the first few doses with food can reduce nausea.
Dose Titration Schedule
Week 2: 0.18 mg three times daily (0.54 mg/day). Week 3: 0.35 mg three times daily (1.1 mg/day). Thereafter the daily dose may be increased by 0.54 mg every week, always divided into three doses, until an optimal effect is reached. Most patients obtain good control between 0.35 mg/day and 2.1 mg/day.
Maintenance Dose
The usual maintenance range is 0.35–3.3 mg pramipexole per day in three divided doses. The maximum recommended dose is 3.3 mg/day. When pramipexole is added to levodopa, the levodopa dose can usually be reduced by 10–30% as the pramipexole dose is increased.
Adults — Restless Legs Syndrome
Starting Dose
Take one 0.088 mg tablet once daily, 2–3 hours before bedtime. This timing aligns the drug's peak effect with the typical onset of symptoms in the evening and night.
Dose Titration
If symptoms are not adequately controlled, the dose may be doubled every 4–7 days: 0.18 mg, then 0.35 mg, up to a maximum of 0.54 mg pramipexole once daily. Use the lowest effective dose to minimize the long-term risk of augmentation.
Review and Drug Holidays
The response to pramipexole in restless legs syndrome should be reviewed after 3 months. If effect diminishes or augmentation appears, an alternative treatment (gabapentin enacarbil, pregabalin, rotigotine patch or iron replacement) should be considered. Dose should always be reduced gradually before switching.
Renal Impairment
| Creatinine Clearance | Starting Dose | Maximum Daily Dose |
|---|---|---|
| > 50 mL/min (normal or mild impairment) | 0.088 mg three times daily | 3.3 mg/day |
| 20–50 mL/min (moderate impairment) | 0.088 mg twice daily | 1.57 mg/day in two doses |
| < 20 mL/min (severe impairment) | 0.088 mg once daily | 1.1 mg/day in one dose |
| Haemodialysis | Generally not recommended | Specialist assessment required |
Children and Adolescents
Pramipexole Teva is not recommended for use in children and adolescents under 18 years of age because safety and efficacy have not been established in this population. Idiopathic Parkinson's disease does not occur in children. Restless legs syndrome can occur in young people but should be treated by a paediatric specialist, usually with iron supplementation and non-pharmacological measures in the first instance.
Elderly Patients
Pramipexole clearance is approximately 30% lower in elderly patients because of an age-related decline in renal function. The same titration schedule is used, but dose increases should usually be slower and the final maintenance dose is often lower. Elderly patients are more susceptible to orthostatic hypotension, hallucinations and confusion, and they are more vulnerable to falls if sleep attacks occur. Regular review of cognition, mood and cardiovascular status is recommended.
Missed Dose
If you miss a dose, take it as soon as you remember, unless it is almost time for the next dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If several doses are missed or treatment has been interrupted for more than a few days, contact your prescriber: resuming the full dose directly may be poorly tolerated and retitration may be required.
Stopping Treatment (Tapering)
Abrupt withdrawal can cause dopamine agonist withdrawal syndrome (DAWS), with anxiety, panic attacks, depression, sweating, pain, nausea and drug craving lasting days to weeks. Very rarely, a neuroleptic malignant syndrome-like reaction with fever, severe muscle rigidity and altered consciousness has been reported. Pramipexole should be reduced gradually: typically by 0.54 mg per day every few days until 0.54 mg per day is reached, then by 0.264 mg per day, under medical supervision.
Overdose
There is limited experience with pramipexole overdose. Symptoms observed have included nausea, vomiting, hyperkinesia, hallucinations, agitation and hypotension. If overdose is suspected, seek emergency medical attention. Treatment is supportive; activated charcoal may be considered if ingestion is very recent, and blood pressure, ECG and mental status should be monitored. There is no specific antidote.
What Are the Side Effects of Pramipexole Teva?
Like all medicines, Pramipexole Teva can cause side effects, although not everyone who takes it will experience them. The frequency categories below follow the standard pharmacovigilance convention used by the European Medicines Agency and most national regulators. Many of the dose-dependent side effects (nausea, dizziness, hypotension) are concentrated in the first weeks of treatment and improve with continued therapy.
Very Common
- Nausea
- Dizziness
- Dyskinesias (abnormal involuntary movements — mainly when combined with levodopa)
- Somnolence (daytime sleepiness)
Common
- Headache
- Fatigue
- Constipation
- Vomiting
- Abnormal dreams or vivid dreams
- Insomnia
- Confusion
- Hallucinations (visual > auditory)
- Peripheral oedema (ankle or leg swelling)
- Orthostatic hypotension (dizziness on standing)
- Hypotension
- Blurred vision or reduced visual acuity
- Decreased appetite
- Restlessness or agitation
- Amnesia
Uncommon
- Sudden onset of sleep without warning
- Pathological gambling
- Compulsive shopping or spending
- Binge or compulsive eating
- Hypersexuality or increased libido
- Delusions and paranoid thinking
- Hyperkinesia
- Pneumonia
- Weight changes (gain or loss)
- Heart failure
- Dyspnoea (shortness of breath)
- Hiccups
- Syncope (fainting)
Rare / Not Known
- Dopamine agonist withdrawal syndrome (DAWS) — on abrupt discontinuation
- Neuroleptic malignant syndrome-like reaction — on abrupt withdrawal
- Punding (repetitive stereotyped behaviours)
- Mania
- Inappropriate ADH secretion (SIADH)
- Severe allergic reaction including anaphylaxis and angioedema
- Augmentation in restless legs syndrome (long-term use)
- Suicidal ideation
Contact emergency services or go to the nearest emergency department if you experience: angioedema (swelling of face, lips, tongue or throat with difficulty breathing or swallowing); sudden severe shortness of breath or chest pain; collapse or loss of consciousness; severe muscle rigidity with high fever and confusion after any dose change; or any new thoughts of suicide or self-harm.
Impulse Control Disorders — Detailed Guidance
Impulse control disorders (ICDs) are among the most clinically important and often under-recognized adverse effects of dopamine agonist therapy. Prospective studies suggest that some form of ICD develops in 13–17% of patients with Parkinson's disease treated with dopamine agonists over several years, with pramipexole having a particular association with problem gambling and hypersexuality. ICDs typically develop insidiously and may initially be hidden from the treating physician by the patient or family. Systematic screening — for example, using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP) — is now recommended at every clinical review.
If an impulse control disorder develops, the first step is usually a gradual dose reduction of pramipexole, typically combined with an increase in levodopa or another non-agonist therapy to maintain motor control. If symptoms persist, complete discontinuation of pramipexole may be necessary. The behaviours usually resolve or substantially improve after discontinuation, although significant financial or relational damage may already have occurred. Psychological support, family counselling and, where appropriate, specialist addiction services should be offered.
Augmentation in Restless Legs Syndrome
Augmentation is a paradoxical worsening of restless legs symptoms over time on dopaminergic therapy. Characteristic features are an earlier onset of symptoms during the day, shorter latency to symptoms at rest, spread of symptoms from the legs to the arms or trunk, and shorter duration of benefit from each dose. Augmentation should be distinguished from tolerance or disease progression. When augmentation is suspected, the dose should not simply be increased; rather, pramipexole should be tapered and replaced with a non-dopaminergic agent such as gabapentin enacarbil or pregabalin, or low-dose rotigotine patches under specialist supervision. Iron status should always be reassessed, because iron deficiency is an important reversible driver of augmentation.
How Should You Store Pramipexole Teva?
Proper storage of pramipexole is important to preserve the potency of the tablet and to prevent accidental ingestion by children or pets, for whom even one low-strength tablet may cause marked adverse effects. Always check the packaging for specific storage information, as manufacturer details can vary slightly between countries and batches.
Standard Storage Conditions
Store the tablets at room temperature, not exceeding 30 °C (86 °F), in the original blister packaging. Do not transfer the tablets to a different container, such as a weekly pill organizer, until shortly before you intend to take them, as removing them from the protective blister can expose the medication to humidity and light. Refrigeration is not required, and the tablets should not be frozen.
Expiry Date
Do not use Pramipexole Teva after the expiry date (marked "EXP" or a similar label) printed on the carton and blister. The expiry date refers to the last day of that month. Using out-of-date medicine may result in reduced efficacy and is not recommended. If a blister is damaged, torn or visibly wet, do not use the tablets it contains and consult your pharmacist.
Disposal
Unused pramipexole should not be thrown into household rubbish or flushed down the toilet, because of the risk of environmental contamination and accidental exposure. Return unused or expired medication to your local pharmacy, which can dispose of it according to national and European regulations. These simple measures protect children, pets and the environment.
What Does Pramipexole Teva Contain?
Active Ingredient
Each tablet contains pramipexole dihydrochloride monohydrate as the active ingredient. Labelling conventions differ internationally: in the European Union and many other regions the strength is expressed as pramipexole base (0.088 mg), while in the United States and a few other markets it is expressed as the salt (0.125 mg). These two labels refer to the same amount of drug and the same tablet.
Other Ingredients (Excipients)
Generic tablets such as Pramipexole Teva typically contain standard pharmaceutical excipients, which may include mannitol, maize starch, colloidal anhydrous silica, povidone and magnesium stearate. Exact formulation details can vary between batches and strengths. If you have known allergies or intolerances — for example, to lactose or specific dyes — check the patient information leaflet that accompanies your pack, or ask your pharmacist for the full qualitative composition of your batch. No formulation of Pramipexole Teva contains gluten.
Appearance and Identification
The 0.088 mg tablet is typically a small, round, white or off-white tablet. The exact embossing, scoring and shape will vary by manufacturer and by market. If your tablet appearance changes markedly between prescriptions, confirm with your pharmacist that the correct medicine has been dispensed.
Frequently Asked Questions About Pramipexole Teva
Pramipexole Teva contains pramipexole, a non-ergot dopamine agonist. It is licensed for the symptomatic treatment of the signs and symptoms of idiopathic Parkinson's disease — either alone in early disease or combined with levodopa in advanced disease — and for the symptomatic treatment of moderate to severe primary restless legs syndrome in adults at doses up to 0.54 mg of pramipexole base per day. It does not alter the underlying disease progression.
For Parkinson's disease, the starting dose is one 0.088 mg tablet three times daily (total 0.264 mg/day), doubled every 5–7 days up to a typical maintenance dose of 0.35–3.3 mg/day divided into three doses. For restless legs syndrome, the starting dose is one 0.088 mg tablet once daily 2–3 hours before bedtime, doubled every 4–7 days up to a maximum of 0.54 mg daily. Dose must be reduced in renal impairment. Always follow the individual titration plan prescribed by your doctor.
The most common side effects are nausea, dizziness, somnolence, headache, constipation, fatigue, abnormal dreams, peripheral oedema and orthostatic hypotension. Hallucinations are common in Parkinson's disease, particularly in elderly patients. Pramipexole can cause sudden onset of sleep without warning and impulse control disorders such as pathological gambling, hypersexuality or compulsive shopping. Most dose-dependent effects improve with slow titration and continued use.
No. Pramipexole should never be stopped abruptly. Sudden discontinuation can cause dopamine agonist withdrawal syndrome (DAWS) with anxiety, depression, panic attacks, sweating, pain and drug craving, and very rarely a neuroleptic malignant syndrome-like reaction. The dose should be tapered gradually, typically by 0.54 mg per day every few days until 0.54 mg/day is reached, then by 0.264 mg per day, under medical supervision.
Yes. Pramipexole and other dopamine agonists can trigger impulse control disorders in a clinically significant minority of patients — roughly 13–17% over several years of Parkinson's disease treatment. These include pathological gambling, hypersexuality, compulsive shopping, binge eating and punding. Patients and families should be warned before treatment starts, screened at every visit, and any new such behaviour reported promptly. Dose reduction or discontinuation usually resolves the problem.
Pramipexole is almost entirely eliminated by the kidneys, so dose and dosing frequency must be reduced in renal impairment. In moderate impairment (creatinine clearance 20–50 mL/min) the starting dose is 0.088 mg twice daily, and in severe impairment (creatinine clearance <20 mL/min) 0.088 mg once daily. Pramipexole is generally not recommended for patients on haemodialysis. Your doctor will check kidney function before and during treatment.
Yes. The 0.088 mg figure refers to pramipexole base, while 0.125 mg refers to the same quantity expressed as pramipexole dihydrochloride monohydrate (the salt form). Both labels describe the same tablet. In the European Union the base convention is standard; in the United States the salt convention is often used. Never use "0.088" and "0.125" mg tablets as if they were different strengths.
References
This article is based on peer-reviewed medical literature, international clinical guidelines and approved prescribing information. Medical claims are supported by the highest available level of evidence (Level 1A where possible).
- European Medicines Agency (EMA). "Sifrol (pramipexole) — Summary of Product Characteristics." EMA/CHMP, most recent revision.
- U.S. Food and Drug Administration (FDA). "Mirapex (pramipexole dihydrochloride) tablets — Prescribing Information." Boehringer Ingelheim / FDA.
- Movement Disorder Society Evidence-Based Medicine Review. "International consensus statement on the management of patients with Parkinson's disease: dopamine agonists." Movement Disorders, 2018 update. DOI: 10.1002/mds.27372
- National Institute for Health and Care Excellence (NICE). "Parkinson's disease in adults: diagnosis and management." NICE guideline [NG71], updated.
- Winkelman JW, Armstrong MJ, Allen RP, et al. "Practice guideline summary: Treatment of restless legs syndrome in adults." Neurology, 2016; 87(24): 2585-2593.
- Weintraub D, Koester J, Potenza MN, et al. "Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients." Archives of Neurology, 2010; 67(5): 589-595.
- Garcia-Borreguero D, Silber MH, Winkelman JW, et al. "Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG and RLS-foundation." Sleep Medicine, 2016; 21: 1-11.
- Rascol O, Brooks DJ, Korczyn AD, et al. "A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa." New England Journal of Medicine, 2000; 342(20): 1484-1491.
- Parkinson Study Group CALM Cohort Investigators. "Long-term effect of initiating pramipexole versus levodopa in early Parkinson disease." Archives of Neurology, 2009; 66(5): 563-570.
- British National Formulary (BNF). "Pramipexole." NICE/BNF, current edition.
- World Health Organization. "WHO Model List of Essential Medicines — 23rd List." WHO, 2023.
Editorial Team
This article has been written and reviewed by iMedic's medical editorial team, which includes specialists in neurology, movement disorders, sleep medicine and clinical pharmacology. Our content follows international medical guidelines and the GRADE evidence framework.
iMedic Medical Editorial Team — Specialists in Neurology and Clinical Pharmacology with expertise in Parkinson's disease and restless legs syndrome therapeutics.
iMedic Medical Review Board — Independent panel of medical experts who review all content according to WHO, EMA, FDA, AASM and MDS guidelines.
Last medical review: | Published:
Our editorial process ensures accuracy, currency and impartiality. We have no commercial funding and accept no pharmaceutical sponsorship. Read more about our editorial standards and medical team.